Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

No. 420 Fuma Road, Fuzhou, Fujian, China

Also known as:

fujian cancer hospital

Clinical Trials

156

72 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

54.5%

Not Applicable

12.8%

Phase 3

10.3%

Phase 1

6.4%

Early Phase 1

1.9%

Phase 4

1.9%

Trial Status Distribution

Active, not recruiting

1.3%

Completed

5.8%

Enrolling By Invitation

1.9%

Not yet recruiting

43.0%

Recruiting

14.7%

Unknown

30.1%

Withdrawn

3.2%

Clinical Trials

Trials sponsored by this organization (156)

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Phase 2

Not yet recruiting

interventional

Feb 202727 participants

Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer

Phase 2

Not yet recruiting

interventional

Sep 202650 participants

A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity Reaction and Its Correlation With Biomarkers

Not Applicable

Not yet recruiting

interventional

Sep 2026380 participants

A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer

Phase 3

Not yet recruiting

interventional

Sep 2026486 participants

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Phase 2

Not yet recruiting

interventional

Aug 2026130 participants

Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer

Phase 2

Not yet recruiting

interventional

Jun 202635 participants

Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer

Recruiting

observational

Jun 2026100 participants

Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC

Phase 2

Enrolling By Invitation

interventional

Apr 202620 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations